Project Grant R01AI192944
Award Date 7/23/26
Completion Date 6/30/31
Dollars Obligated $751K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded New York University $230,340 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antibody-based therapies that block pathogenic donor-specific antibody (DSA) responses in transplant rejection. The three-year training plan, performed at New York University School of Medicine in New York, New York, aims to engineer recombinant antibodies from pathogenic DSAs into blocking...
- The University of Pittsburgh received a $679,937 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on mechanisms and therapeutic targeting of T cell regulation in heart allograft recipient monkeys. The 5-year project aims to investigate the impact of cytokine modulation and administration of novel, donor-specific chimeric antigen receptor regulatory T cells (CARTREG) on promoting long-term...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded $452,835 to the University of Pittsburgh on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel nanobiologic approaches for reversing graft rejection in transplant recipients. The research targets innate immune memory responses that drive persistent T-cell–mediated rejection despite standard immunosuppressive treatment. The project investigates the role of heat shock...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $172,160 on October 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support investigator-initiated research on the role of PTEN in homeostatic repopulation after induction therapy in kidney transplantation, led by Principal Investigator Michael K. Okoreeh. The funded research investigates how phosphatase and tensin homologue (PTEN) regulates memory T cell differentiation and...
- The National Institute of Allergy and Infectious Diseases awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $690,359 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of donor-specific antibody production in kidney transplantation. The research addresses antibody-mediated rejection (ABMR), a leading cause of renal transplant loss, by examining the role of lymphocyte activation gene 3...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $243,000 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model fibroblast-cholangiocyte interactions in chronic ductopenic rejection using primary human cholangiocyte organoids. Chronic ductopenic rejection is the most common immunologic cause of liver allograft loss in children. The research uses human liver tissue samples and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $218,728 on February 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support postdoctoral research on post-transcriptional regulation of T cells. The research investigates the role of an RNA-binding protein in T cell-driven inflammatory disease using graft-versus-host disease as a model system, and seeks to elucidate the mechanistic basis for how this protein...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $162,792 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI202489) to develop and validate an antibody-mediated rejection (AMR)-on-a-chip platform that recapitulates key pathological features of AMR in kidney transplant rejection in vitro. The recipient will engineer a glomerulus-on-a-chip model using human induced pluripotent stem cell-derived renal...